Eli Lilly's Foundayo (Orforglipron) Receives FDA Approval for Obesity Treatment as Company Reports Strong Q1 2026 Results
Decision brief
Answer first · skim in under a minute
Eli Lilly announces FDA approval of Foundayo (orforglipron) for obesity treatment alongside positive Phase 3 results and raised full-year guidance in Q1 2026.
The FDA approved Eli Lilly's Foundayo (orforglipron) on April 1, 2026, as the first oral GLP-1 receptor agonist for obesity treatment. This approval came alongside strong Q1 2026 results, with revenue reaching $19.8 billion, up 56% year-over-year.
Contents10 sections
Key Takeaways
- FDA approved Foundayo (orforglipron) on April 1, 2026, for adults with obesity or overweight with weight-related comorbidities—the first oral GLP-1 in this class Source: FDA.gov
- Phase 3 trials (NCT05869903, NCT05872620) demonstrated efficacy across 3,127+ participants in obesity and type 2 diabetes Source: ClinicalTrials.gov
- Eli Lilly Q1 2026 revenue hit $19.8 billion (56% growth), with reported EPS up 170% to $8.26; full-year guidance raised to $82.0-$85.0 billion Source: Lilly Investor Relations
- Approval marks first new molecular entity granted under the Commissioner's National Priority Voucher (CNPV) pilot program and fastest NME approval since 2002
What Did the FDA Approve on April 1, 2026?
The FDA granted approval to Foundayo (orforglipron) for adults with obesity or overweight with at least one weight-related comorbid condition. This approval represents a landmark in metabolic disease treatment because orforglipron is the first oral GLP-1 receptor agonist approved for obesity. Learn more about weight management treatments.
Unlike existing injectable treatments such as Novo Nordisk's Wegovy (semaglutide) or Eli Lilly's own Zepbound (tirzepatide), Foundayo offers patients a daily pill option. This oral formulation removes barriers for patients who prefer pills over injections.
The approval came under the FDA's Commissioner's National Priority Voucher (CNPV) pilot program. This marked the first new molecular entity approved under this program and represented the fastest NME approval since 2002.
How Does Orforglipron Work?
Orforglipron is a small-molecule GLP-1 receptor agonist that binds allosterically to a transmembrane pocket on the GLP-1 receptor. This differs from peptide-based agonists like semaglutide and tirzepatide.
The drug activates Gs protein signaling and drives cAMP accumulation. It exhibits Gs-biased signaling with minimal β-arrestin recruitment. This signaling profile may contribute to sustained effects and reduced gastrointestinal side effects.
The small-molecule design provides oral bioavailability without complex formulations. It resists gastric acidity and proteolytic enzymes, allowing efficient absorption as a daily tablet.
What Clinical Trials Supported the Approval?
Foundayo's approval was supported by multiple Phase 3 trials registered on ClinicalTrials.gov and NovaPharma clinical trial coverage:
| Trial ID | Study Name | Phase | Enrollment | Population |
|---|---|---|---|---|
| NCT05869903 | SURMOUNT-1 | 3 | 3,127 | Obesity/overweight with comorbidities |
| NCT05872620 | SURMOUNT-2 | 3 | 1,613 | Obesity/overweight with type 2 diabetes |
| NCT06584916 | SURMOUNT-5 | 3b | 376 | Weight maintenance post-tirzepatide/semaglutide |
The SURMOUNT-1 trial evaluated orforglipron over 72 weeks in adults with obesity or overweight and weight-related comorbidities. Participants with prediabetes continued in an extension phase for an additional two years.
SURMOUNT-2 assessed orforglipron versus placebo on body weight in participants with obesity or overweight and type 2 diabetes over 77 weeks. The trial completed in August 2025.
What Were Eli Lilly's Q1 2026 Financial Results?
Eli Lilly reported strong financial performance in Q1 2026, driven by volume growth across key products. Revenue increased 56% to $19.8 billion compared to the prior year period.
Reported earnings per share (EPS) increased 170% to $8.26. Non-GAAP EPS rose 156% to $8.55. The growth reflected strong demand for metabolic disease treatments.
Following the strong quarter, Lilly raised full-year guidance:
- Revenue guidance: $82.0-$85.0 billion (previous range not specified)
- Non-GAAP EPS guidance: $35.50-$37.00
The company also advanced its business development strategy with acquisitions including Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics.
What Other Pipeline Updates Did Lilly Report?
Lilly reported positive Phase 3 results for Foundayo in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk. This dual indication potential expands the addressable market.
In oncology, Lilly announced positive results for Jaypirca (pirtobrutinib) in combination with venetoclax and rituximab for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Jaypirca received traditional FDA approval on December 3, 2025, for patients previously treated with a covalent BTK inhibitor. The BRUIN-CLL-321 trial showed median progression-free survival of 11.2 months versus 8.7 months with control therapy.
The company also reported results for Taltz (ixekizumab) and Zepbound combination therapy in adults with psoriasis and obesity or overweight. A Phase 3b trial (NCT06588283) demonstrated superior efficacy compared to ixekizumab alone. 27.1% of participants achieved PASI 100 skin clearance plus ≥10% weight reduction versus 5.8% with ixekizumab monotherapy.
How Does This Impact the Obesity Treatment Market?
The approval positions Lilly to compete more effectively against Novo Nordisk in the obesity market. The oral formulation may capture patients who prefer pills over injections.
The obesity treatment market has faced supply constraints. Both Lilly and Novo Nordisk have struggled to meet demand for injectable GLP-1 products. The oral formulation of Foundayo may offer manufacturing advantages. Scaling production will remain critical for market penetration.
Lilly's ability to advance multiple programs across different therapeutic areas demonstrates strong research and development capabilities. The company's diversified pipeline spans metabolic diseases, oncology, and immunology.
What Is the Market Structure?
Novo Nordisk currently leads the obesity market with Wegovy (semaglutide), a weekly injectable GLP-1 receptor agonist. Lilly's own Zepbound (tirzepatide), a dual GIP/GLP-1 receptor agonist, competes in the same space.
Foundayo's oral administration differentiates it from both competitors. Patient preference for oral versus injectable therapy varies. Some patients accept injections for efficacy. Others avoid injections due to needle phobia, injection site reactions, or convenience factors.
Other oral GLP-1 candidates are in development. Ascletis Pharma's ASC30 completed Phase II enrollment for oral GLP-1 diabetes treatment. This competitive dynamic will intensify as more oral options reach the market. See our metabolic health coverage for updates.
Frequently Asked Questions
What makes Foundayo different from existing obesity treatments?
Foundayo (orforglipron) is the first oral GLP-1 receptor agonist approved for obesity, offering a daily pill alternative to weekly injections like Wegovy and Zepbound.
When was Foundayo approved by the FDA?
The FDA approved Foundayo on April 1, 2026, under the Commissioner's National Priority Voucher (CNPV) pilot program, marking the fastest new molecular entity approval since 2002.
How did Eli Lilly perform in Q1 2026?
Eli Lilly reported Q1 2026 revenue of $19.8 billion, up 56% year-over-year, with reported EPS increasing 170% to $8.26. The company raised full-year guidance to $82.0-$85.0 billion.
What clinical trials supported Foundayo's approval?
Foundayo's approval was supported by Phase 3 trials including NCT05869903 (SURMOUNT-1, 3,127 participants) and NCT05872620 (SURMOUNT-2, 1,613 participants), demonstrating efficacy in obesity and type 2 diabetes.
Primary Sources
- U.S. Food and Drug Administration. FDA Approval Letter for Foundayo (orforglipron). April 1, 2026. FDA.gov
- ClinicalTrials.gov. NCT05869903: Study of Orforglipron in Participants With Obesity or Overweight. clinicaltrials.gov/study/NCT05869903
- ClinicalTrials.gov. NCT05872620: Study of Orforglipron in Participants With Obesity/Overweight and Type 2 Diabetes. clinicaltrials.gov/study/NCT05872620
- Eli Lilly and Company. Lilly Reports First-Quarter 2026 Financial Results, Raises Full-Year Guidance. Investor Relations. investor.lilly.com
- U.S. Securities and Exchange Commission. Form 8-K: Eli Lilly and Company. Q1 2026. SEC.gov
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Foundayo (orforglipron).
Unlock full calendar →Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
